Unimed's Revenue Increases by 9% as of September 30, 2024
Unimed's revenue as of September 30, 2024, has increased by 9% compared to the same period last year, reaching 104.3 billion dinars.
This commercial performance is achieved thanks to a 78% increase in sales on the hospital market and a 6% increase in pharmacy revenue compared to September 30, 2023.
Production and Investments
The production of units (ampoules, bottles, syringes, and pouches) stands at 190,206,374 as of September 30, 2024, representing a slight 1% decrease compared to the same period in 2023. Meanwhile, investments (intangible and tangible) made as of September 30, 2024, amount to 2.3 billion dinars, in line with the company's planned investment expansion plan.
Debt and Financing
The long-term debt as of September 30, 2024, stands at 24.3 billion dinars. Short-term debts for the same period amount to 25.3 billion dinars, comprising:
- Bank credit repayments due within a year: 8.2 billion dinars
- Leasing credit repayments: 0.2 billion dinars
- Management credits: 16.9 billion dinars
